Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients.

ABSTRACT:

Background

Although the efficacy of iron sucrose (IS) and ferric carboxymaltose (FCM) in treating anemia in hemodialysis (HD) patients has been studied individually, a comparison of these two intravenous iron formulations has not yet been performed in HD patients.

Methods

We performed a retrospective audit on records of 221 stable HD patients from different HD centers in the Netherlands, who were switched from IS to FCM on a 1:1 ratio. To assess the effect of the switch on iron status parameters, data from 3 time points before and 3 time points after the switch were analyzed using linear mixed effects models. Subanalyses were done in 2 subgroups of patients anemic or iron deficient at baseline.

Results

Hemoglobin increased in all groups (anemic [1.4 g/dL, P < 0.001] i

SUBMITTER: Hofman JMG 

PROVIDER: S-EPMC6149056 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature